1 / 21

Trial Vignettes

Trial Vignettes . TRITON-TIMI 38 ARMYDA 4 + 5 OPTIMA. Cameron G Densem. NO CONFLICT OF INTEREST TO DECLARE. TR ial to Assess I mprovement in T herapeutic O utcomes by Optimizing Platelet Inhibitio N with Prasugrel- TIMI 38. Dual antiplatelet therapy Limitations of Clopidogrel

dimaia
Download Presentation

Trial Vignettes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Trial Vignettes TRITON-TIMI 38 ARMYDA 4 + 5 OPTIMA Cameron G Densem

  2. NO CONFLICT OF INTEREST TO DECLARE

  3. TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-TIMI38 • Dual antiplatelet therapy • Limitations of Clopidogrel • Prasugrel, novel ADP inhibitor • More rapid, consistent and effective • JUMBO-TIMI 26 Bleeding MACE

  4. 13 608 ACS Patients Scheduled PCI Known anatomy Clopidogrel 300mg Aspirin 75-162mg Prasugrel 60mg Loading Exclusions: Increased bleed risk Anaemia Low platelets Intracranial pathology Thienopyridine 5/7 PCI Aspirin 75-162mg Prasugrel 10mg Chronic 6-15 months Clopidogrel 75mg Primary endpoint: CV Death Non-fatal MI Non-fatal CVA Secondary endpoints: Stent thrombosis (ARC) Bleeding Primary endpoint and TVR

  5. 99% had PCI 94% had at least 1 stent 47% at least 1 DES Median FU 14.5 mths 2.2% absolute reduction 19% relative reduction

  6. Prasugrel Clopidogrel HR P Cardiovascular Death 2.1% 2.4% 0.89 0.31 Non fatal MI 7.3% 9.5% 0.76 <0.001 10 Endpoint diabetics 12.2% 17.0% 0.70 <0.001 10 Endpoint non- diabetics 9.2% 10.6% 0.86 0.02 Urgent TVR 2.5% 3.7%% 0.66 <0.001 Stent thrombosis 1.1% 2.4% 0.48 <0.001 (def/prob ARC) BMS 0.52 <0.001 DES 0.43 <0.001

  7. Bleeding Prasugrel Clopidogrel HR P Non CABG TIMI Major 2.4% 1.8% 1.32 0.03 Life threatening 1.4% 0.9% 1.52 0.01 Fatal 0.4% 0.1% 4.19 0.002 Intracranial 0.3% 0.3% 1.12 0.74 Major/minor TIMI 5.0% 3.8% 1.31 0.002 Transfusion 4.0% 3.0% 1.34 <0.001 CABG TIMI major 13.4% 3.2% 4.73 <0.001

  8. Post Hoc Analysis Prasugrel Clopidogrel HR P Prev CVA/TIA 23.0% 16.0% 1.54 0.04 Age >75 % % 0.99 0.92 Weight <60Kg % % 1.03 0.89 Age<75, Weight >60Kg 10.2%12.5% 0.80 <0.001 No CVA/TIA End point: death any cause, non-fatal MI/CVA, non-CABG related nonfatal TIMI major bleed

  9. Conclusions • Reduction in ischaemic events • At a cost of increased bleeding • Subgroups • Diabetics • Age, CVA, body weight • For every 100 patients treated: • 23 MIs prevented • Excess of 6 non CABG TIMI major bleeds “…clinicians need to weigh the benefits and risks of intensive inhibition of platelet aggregation….”

  10. Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty 4 and 5 • Debate surrounding optimal dosage and timing of antiplatelet agents around time of PCI • Potential benefit of 600mg Clopiogrel loading Death MI TVR ARMYDA-2

  11. 350 patients Clopidogrel naive Angina or NSTEMI Unknown anatomy ARMYDA-5 Clopidogrel 600mg Pretreatment n=174 Coronary Angiography PCI indicated 4-8hrs Pre- PCI Coronary Angiography Clopidogrel 600mg treatment n=176 Coronary Angioplasty 30 day Primary endpoint: CV Death Non-fatal MI TVR Secondary endpoints: Bleeding Biomarker release

  12. 11% 8% Composite primary endpoint: 30 day death, MI, TVR (all events MIs) p=0.56 5% Minor bleeding at 30 days 4% p=ns

  13. 464 patients on Clopidogrel>10 days Angina or NSTEMI Unknown anatomy ARMYDA-4 Clopidogrel Reloading 600mg n=230 4-8hrs Pre- PCI Placebo n=234 Exclusions: Primary PCI High bleed risk Low platelets Recent CABG Coronary Angiography CABG n=42 PCI n=180 PCI n=180 Medical n=62 30 day Primary endpoint: CV Death Non-fatal MI TVR Secondary endpoints: Biomarker release Bleeding

  14. Composite primary endpoint: 30 day death, MI, TVR Individual events at 30 days 8% % 8% % 7% 7% p=0.96 MI definition: post-procedural increase of CK-MB >3 times above UNL Post PCI peak levels of Troponin I (ng/ml) Bleeding 4% 4% % Placebo 0.52 +/- 2.2 0.39 +/- 1.1 Clopidogrel

  15. Conclusions • 600mg Clopidogrel preloading confers no benefit relative to intra loading • 600mg Clopidogrel reloading confers no extra benefit if on chronic therapy • Small sample sizes

  16. OPtimal TIMing of PCI in Unstable Angina • Current guidelines recommend an early invasive strategy in high risk NSTE-ACS • The precise timing of early PCI is controversial. • Immediate PCI may prevent (spontaneous) cardiac events • Deferred PCI may lead to less peri-procedural complications

  17. High Risk ACS Coronary Angiography N=251 OPTIMA Exclusions n=109: No significant CAD 55 CABG 27 ISR 9 Clinically driven immediate PCI 8 Culprit lesion not amenable for PCI 6 CTO 4 Abciximab Aspirin Clopidogrel Immediate PCI n=73 Deferred PCI n=69 30 day Primary endpoint: CV Death Non-fatal MI TVR

  18. Deferment

  19. Primary Endpoint 30 days: CV Death, Non-fatal MI, TVR No Mortality

  20. Infarct Size peak CKMB: p<0.01 % CKMB (median): 9.8 (ng/L) 4.9 (ng/L)

  21. Conclusions • Immediate PCI increases rate of “peri-procedural” CK-MB release • Small, select group of patients • Preliminary data • Underpowered, planned to recruit 600 • ?CK-MB best biomarker • How long waiting for first cath

More Related